The ZBTB20 antibody is a crucial tool in biomedical research for studying the zinc finger and BTB domain-containing protein 20 (ZBTB20), a transcription factor involved in diverse physiological and pathological processes. ZBTB20 regulates gene expression by binding to specific DNA sequences, playing roles in liver development, neuronal differentiation, glucose metabolism, and immune response modulation. Its dysfunction has been linked to hepatocellular carcinoma, Alzheimer's disease, and diabetes. Researchers use ZBTB20 antibodies primarily in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect protein expression levels, cellular localization, and tissue distribution. These antibodies are often generated in hosts like rabbits or mice, targeting specific epitopes of human, mouse, or rat ZBTB20. Validation typically includes knockout cell or tissue controls to confirm specificity. Recent studies highlight its potential as a therapeutic target, particularly in cancers where ZBTB20 overexpression correlates with tumor progression. However, antibody performance may vary depending on post-translational modifications or isoform expression. Commercial ZBTB20 antibodies usually provide data on recommended dilutions and validated applications, though independent verification remains essential for experimental rigor. Its growing importance in metabolic and neurological research continues to drive antibody development and optimization.